Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 9/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 9/20 | 0.41 |
| ▸ | AURKA | O14965 | 6/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 6/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 5/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1318413 | 0.88 | PDPK1 (0.45) | PDPK1AURKBAURKAROCK1MTOR | |
| SCHEMBL1317478 | 0.86 | MTOR (0.41) | PDPK1AURKBAURKAROCK1MTOR | |
| SCHEMBL1317985 | 0.85 | MTOR (0.45) | PDPK1AURKBAURKAROCK1MTOR | |
| SCHEMBL2452185 | 0.85 | MTOR (0.45) | PDPK1AURKBAURKAROCK1MTOR | |
| SCHEMBL2446206 | 0.85 | MTOR (0.45) | PDPK1AURKBAURKAROCK1MTOR | |
| SCHEMBL1317359 | 0.85 | MTOR (0.45) | PDPK1AURKBAURKAROCK1MTOR | |
| SCHEMBL1316976 | 0.82 | PDPK1 (0.42) | PDPK1AURKBAURKAROCK1MTOR | |
| SCHEMBL1317660 | 0.81 | PDPK1 (0.51) | PDPK1AURKBAURKAROCK1MTOR | |
| SCHEMBL1326032 | 0.81 | PDPK1 (0.51) | PDPK1AURKBAURKAROCK1MTOR | |
| SCHEMBL1317349 | 0.81 | KDM1A (0.39) | PDPK1AURKBAURKAROCK1MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2362775-B1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2015-08-05 | — | — | EP | disclosed |
| EP-2362775-B1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2015-08-05 | — | — | EP | disclosed |
| US-8697685-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2014-04-15 | — | — | US | disclosed |
| US-20110275611-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2011-11-10 | — | — | US | disclosed |
| US-20110275611-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2011-11-10 | — | — | US | disclosed |
| US-20110275611-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275611-A1 | CHEMICAL COMPOUNDS | PDK1, PDK2, PDK3 | PDPK1 12/4885AURKB 262/4885AURKA 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.